ArticleCurrent oncology (Toronto, Ont.)2026

Late Complications After European Medicines Agency-Approved Chimeric Antigen Receptor T-Cell Therapy in Hematological Malignancies: A Scoping Review.

Michael Eisenmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.